Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
Locoregionally advanced and metastatic melanoma are complex diagnoses with a variety of available treatment options. Intralesional therapy for melanoma has been under investigation for decades; however, it has advanced precipitously in recent years. In 2015, the Food and Drug Administration (FDA) ap...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/5/1404 |
| _version_ | 1797615627219763200 |
|---|---|
| author | Danielle K. DePalo Jonathan S. Zager |
| author_facet | Danielle K. DePalo Jonathan S. Zager |
| author_sort | Danielle K. DePalo |
| collection | DOAJ |
| description | Locoregionally advanced and metastatic melanoma are complex diagnoses with a variety of available treatment options. Intralesional therapy for melanoma has been under investigation for decades; however, it has advanced precipitously in recent years. In 2015, the Food and Drug Administration (FDA) approved talimogene laherparepvec (T-VEC), the only FDA-approved intralesional therapy for advanced melanoma. There has been significant progress since that time with other oncolytic viruses, toll-like receptor agonists, cytokines, xanthene dyes, and immune checkpoint inhibitors all under investigation as intralesional agents. Further to this, there has been exploration of numerous combinations of intralesional therapies and systemic therapies as various lines of therapy. Several of these combinations have been abandoned due to their lack of efficacy or safety concerns. This manuscript presents the various types of intralesional therapies that have reached phase 2 or later clinical trials in the past 5 years, including their mechanism of action, therapeutic combinations under investigation, and published results. The intention is to provide an overview of the progress that has been made, discuss ongoing trials worth following, and share our opinions on opportunities for further advancement. |
| first_indexed | 2024-03-11T07:29:21Z |
| format | Article |
| id | doaj.art-04a5cd51bc0646ee8b90ff933759d836 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T07:29:21Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-04a5cd51bc0646ee8b90ff933759d8362023-11-17T07:23:39ZengMDPI AGCancers2072-66942023-02-01155140410.3390/cancers15051404Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of ProgressDanielle K. DePalo0Jonathan S. Zager1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USADepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USALocoregionally advanced and metastatic melanoma are complex diagnoses with a variety of available treatment options. Intralesional therapy for melanoma has been under investigation for decades; however, it has advanced precipitously in recent years. In 2015, the Food and Drug Administration (FDA) approved talimogene laherparepvec (T-VEC), the only FDA-approved intralesional therapy for advanced melanoma. There has been significant progress since that time with other oncolytic viruses, toll-like receptor agonists, cytokines, xanthene dyes, and immune checkpoint inhibitors all under investigation as intralesional agents. Further to this, there has been exploration of numerous combinations of intralesional therapies and systemic therapies as various lines of therapy. Several of these combinations have been abandoned due to their lack of efficacy or safety concerns. This manuscript presents the various types of intralesional therapies that have reached phase 2 or later clinical trials in the past 5 years, including their mechanism of action, therapeutic combinations under investigation, and published results. The intention is to provide an overview of the progress that has been made, discuss ongoing trials worth following, and share our opinions on opportunities for further advancement.https://www.mdpi.com/2072-6694/15/5/1404advanced melanomain transit metastasesintralesional therapyintratumoral therapylocal therapylocoregional therapy |
| spellingShingle | Danielle K. DePalo Jonathan S. Zager Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress Cancers advanced melanoma in transit metastases intralesional therapy intratumoral therapy local therapy locoregional therapy |
| title | Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress |
| title_full | Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress |
| title_fullStr | Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress |
| title_full_unstemmed | Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress |
| title_short | Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress |
| title_sort | advances in intralesional therapy for locoregionally advanced and metastatic melanoma five years of progress |
| topic | advanced melanoma in transit metastases intralesional therapy intratumoral therapy local therapy locoregional therapy |
| url | https://www.mdpi.com/2072-6694/15/5/1404 |
| work_keys_str_mv | AT daniellekdepalo advancesinintralesionaltherapyforlocoregionallyadvancedandmetastaticmelanomafiveyearsofprogress AT jonathanszager advancesinintralesionaltherapyforlocoregionallyadvancedandmetastaticmelanomafiveyearsofprogress |